FINWIRES · TerminalLIVE
FINWIRES

布蘭特原油價格逼近每桶120美元,據報川普拒絕了伊朗的提議

By

-- 週三,油價大幅上漲,布蘭特原油逼近每桶120美元,此前有報道美國總統川普拒絕了伊朗提出的解除海上封鎖的提議。 布蘭特原油最新上漲7.2%,至每桶119.25美元,盤中一度觸及每桶119.45美元的高點。西德州中質原油上漲7%,至每桶106.91美元。 川普週三告訴Axios新聞網,他將繼續維持美國對伊朗港口的海上封鎖,直到德黑蘭同意達成核協議。伊朗希望在雙方能夠坐下來討論鈾濃縮問題之前,先開放霍爾木茲海峽。 川普週三在社群媒體上發文稱,伊朗「最好盡快醒悟過來」。 一位伊朗高級安全官員告訴伊朗國家電視台Press TV,美國海上封鎖很快就會遭到「切實且前所未有的行動」的回應。 儘管華盛頓和德黑蘭之間的停火協議似乎仍在維持,但雙方的言論仍處於停滯狀態。以色列和黎巴嫩之間也達成了單獨的停火協議。 根據美國有線電視新聞網(CNN)報道,巴基斯坦調解人預計伊朗將在周五之前提出修改後的方案。 盛寶銀行大宗商品策略主管奧勒·漢森週三在一份報告中表示:「原油價格已恢復了受戰爭推動的上漲勢頭。布倫特原油價格自月中短暫跌至每桶86美元後幾乎持續上漲。當時,人們對和平協議的希望以及霍爾木茲海峽短暫重新開放的預期引發了油價的急劇但暫時的回調。」 除了伊朗戰爭之外,市場也正在評估阿聯酋退出石油輸出國組織(歐佩克)的決定所帶來的影響。 漢森表示,此舉標誌著「(阿聯酋的)重大戰略轉變,使其擺脫了多年來限制其充分利用不斷增長的產能的產量配額限制」。 荷蘭國際集團(ING)週三發布的一份報告稱,阿聯酋退出石油輸出國組織(歐佩克)後,計劃增加石油產量。 荷蘭國際集團表示:“然而,在此之前,波斯灣必須達成一項解決方案,確保霍爾木茲海峽的能源運輸暢通無阻。因此,短期內,這一進展對市場影響甚微。但從中長期來看,這意味著市場將獲得更多供應。”

Related Articles

Research

Research Alert: CFRA Downgrades Rating To Sell From Hold On Shares Of Essex Property Trust, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target by $15 to $250 using a narrower equity risk premium and a forward P/FFO of 15.5x, which is in line with the multifamily residential REIT average. We keep our 2026 FFO estimate at $16.15 and lower 2027's by $0.05 to $16.45 on respective revenue projections of $1.94B and $1.98B. Rental revenue is not yet rebounding to historical growth levels. Across the industry, we are seeing inflation in key operating expenses exceeding revenue growth, and this leads to modest gains in cash NOI growth Y/Y. We expect these market conditions to continue as pricing power for ESS and its peers seems to have eased. In particular, ESS has a West Coast portfolio profile that is exposed to significant job layoffs in the technology sector. In our opinion, we have not yet seen the tail risk of major announcements just released in recent weeks. ESS has the challenge of complying with strict housing guidelines in California, leading to the trust historically underperforming peers in other parts of the country.

$ESS
Research

Research Alert: CFRA Keeps Buy Rating On Shares Of Biogen Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our target at $236, 13.8x our new 2027 EPS view, a discount to BIIB's five-year historical forward P/E average of 14.1x. We lower our 2026 EPS view to $15.24 from $16.14 to adjust for the impact from acquired IPR&D. We keep our 2027 EPS view at $17.16. BIIB reported a strong start to 2026, with sales of $2.5B and adjusted EPS of $3.57. We see a successful stabilization of the business after years of decline, due to a 12% Y/Y increase in the growth products portfolio. In our view, during the analyst call, management presented a clear strategic vision centered on the pending $5.6B acquisition of Apellis, expected to close in Q2, which can transform BIIB into a growth company by adding two commercial assets, Syfovre and Empaveli. We think the Apellis deal could bridge a revenue gap until 2028, when the company's late-stage pipeline matures. Via this acquisition, BIIB also gains nephrology expertise and an established infrastructure, which could set its key asset Felzartamab launch for success.

$BIIB
Australia

Starbucks to Sustain Sales Momentum; to Focus on Margins in H2, UBS Says

Starbucks (SBUX) is expected to maintain solid sales momentum on its turnaround strategy, though investor focus is shifting toward margin recovery in H2, UBS said in a note on Wednesday.The brokerage said strong transaction-driven comparable sales growth in Q2 reflected improvements in operations, menu innovation and updated loyalty program.Looking ahead, UBS said continued execution on initiatives such as afternoon beverage platforms, loyalty enhancements, store closures and operational improvements should support sales into H2.UBS also expects margin expansion later in the year, supported by sales leverage, cost savings and easing pressures from tariffs and coffee costs.UBS raised the price target on the stock to $105 from $100 but maintained a neutral rating.Price: $106.10, Change: $+8.82, Percent Change: +9.06%

$SBUX